ClinicalTrials.gg
Status unknownNCT01722942CHAGASICSUpdated Aug 30, 2021

Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death

An interventional study of ICD implantation and amiodarone hydrochloride in Chagas Cardiomyopathy, Non-sustained Ventricular Tachycardia and At Least 10 Points in Rassi Risk Score for Death, sponsored by InCor Heart Institute. Status unknown at 20 sites in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-30.

Sponsored by InCor Heart Institute · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.

Planned enrollment
Largest of 11
1,100 · median 42
Started
2014
with 1 other
No phase
4 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
3 of 14
InCor Heart Institute

Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 with no phase, and was the 5th registered.

Chagas Cardiomyopathy

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

Browse Chagas Cardiomyopathy studies →

Open to participants now

2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Chagas Cardiomyopathy with a site in Brazil, or all of them as a file.
02

Study summary

The primary objective is to compare the efficacy of the treatment using implantable cardioverter defibrillator (ICD) implantation to that of the treatment using amiodarone in the primary prevention of all-cause mortality in high-risk patients with Chagas cardiomyopathy and non-sustained ventricular tachycardia (NSVT).

Read the detailed description

Chagas disease is an endemic problem in Latin America, where millions of people are chronically infected by Trypanosoma cruzi. The disease has also recently become clinically and epidemiologically relevant in several other countries due to social factors related to individuals migration and globalization. Chagas cardiomyopathy occurs in 30%-50% of the infected individuals, leading to considerable morbidity and mortality rates. Sudden cardiac death is the major cause of death in patients with Chagas cardiomyopathy. While implantable cardioverter defibrillator and treatment with amiodarone have been recommended and performed empirically for the secondary prevention in patients with Chagas cardiomyopathy, no consistent scientific evidence exists on the role of these therapeutic strategies for the primary prevention of Sudden cardiac death in patients with Chagas cardiomyopathy and high mortality risk.

The main hypothesis of this study is that implantable cardioverter defibrillator implantation is more efficient in the primary prevention of death in Chagas cardiomyopathy than drug therapy with amiodarone in patients with documented non-sustained ventricular tachycardia.

We should point out that the death risk will be assessed using the Rassi risk score for death prediction validated based on non-invasive variables and, depending on the results of this study, it may guide the indication of implantable cardioverter defibrillator in Chagas cardiomyopathy.

03

Conditions studied

  • Chagas Cardiomyopathy
  • Non-sustained Ventricular Tachycardia
  • At Least 10 Points in Rassi Risk Score for Death

Keywords

  • Chagas cardiomyopathy
  • sudden cardiac death
  • primary prevention of death
  • amiodarone
  • implantable cardioverter defibrillator
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to randomization and any study procedure;
  • Both genders, age > 18 years and \< 75 years;
  • Recent (previous 6 months) documented positive serologic test for Chagas disease in at least two different tests (indirect hemagglutination, indirect immunofluorescence, or ELISA);
  • Presence of at least 10 points in Rassi risk score for death prediction;
  • Presence of at least 1 episode of NSVT on Holter monitoring, defined as > 3 successive beats and duration \< 30 seconds, with HR > 120 bpm is mandatory.

Exclusion criteria

Exclusion Criteria:

  • Participation in another study currently or \< 1 year ago, except for totally unrelated observational studies;
  • Other concomitant cardiovascular disease, including uncontrolled diabetes mellitus (systemic hypertension without target-organ impairment is allowed);
  • Renal dysfunction (serum creatinine > 1.5 mg/dL or (GFR) \< 60 mL/min/1.73m2) or liver dysfunction with diagnosis of cirrhosis or portal hypertension or elevated serum enzymes ( or ALT) > 3 x the upper normal limit;
  • Moderate or severe ;
  • Peripheral polyneuropathy;
  • Hypo or hyper-thyroidism;
  • Current alcoholism or quit for \<2 years;
  • Mental disorder or illicit drug addiction;
  • \< 1 year, because of the disease itself or of comorbidities (including class IV CHF);
  • Pregnancy or breastfeeding;
  • during the study (non-menopausal patients who have not undergone a safe and permanent method);
  • Other for the use of amiodarone: previous intolerance to the drug; HR \< 55bpm; sinus node disease; type II Mobitz; fixed 2:1 AV block; advanced degree atrioventricular block (AV) block; Complete AV block; > 500mseg;
  • Formal indication for the use of amiodarone or defibrillator (NSVT and very disturbing palpitations, presyncope or syncope; SVT; recovery from cardiac arrest);
  • Use of amiodarone in the past 6 months, except if started for \< 2 weeks and if loading dose had been \<10g and maintenance dose ≤100mg/day;
  • Current use of betablocker considered clinically indispensable, with bradycardia \< 55/min or AV block ≥ 1st degree, without pacemaker implantation;
  • Current use of other medications with contraindication to the concomitant use of amiodarone;
  • Persistent or permanent atrial fibrillation;
  • Previous withdrawal from this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants (estimated)

Study arms

  • Active comparator
    ICD group

    ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.

    Procedure: ICD implantation

  • Active comparator
    Amiodarone Group

    Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen: * Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis; * After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted.

    Drug: amiodarone hydrochloride

Interventions

  • ProcedureICD implantation

    ventricular ICD implantation

    Also known as: ICD

  • DrugAmiodaroneStudies of AmiodaroneAmiodarone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    amiodarone prescription

    Also known as: amiodarone

06

What researchers measure

Primary outcomes

  1. all cause mortality

    All cause mortality

    Time frame: three and half years

Secondary outcomes

  1. Cardiac mortality

    cardiac mortality

    Time frame: three and half years

  2. Sudden cardiac death

    Sudden cardiac death

    Time frame: three and half years

  3. Worsening heart failure warranting hospitalization

    Worsening heart failure warranting hospitalization

    Time frame: three and half years

  4. Need for cardiac stimulation in the ICD arm

    Need for cardiac stimulation in the ICD arm

    Time frame: three and half years

  5. Need for pacemaker implantation in the amiodarone therapy arm

    Need for pacemaker implantation in the amiodarone therapy arm

    Time frame: three and half years

Other outcomes

  1. Subgroup analyses will include gender, age ≥ or < 60 years, occurrence or not of atrial fibrillation, New York Heart Association (NYHA) functional class I and II versus III and IV, as well as Rassi score points.

    Subgroup analyses will include gender, age ≥ or \< 60 years, occurrence or not of atrial

    Time frame: three and half years

07

Study locations

8 of 20 sites recruiting
  • Hospital Ana Nery
    Salvador, BA, Brazil
    Not yet recruiting
  • Hospital Universitário Walter Cantideo
    Fortaleza, CE, Brazil
    Recruiting
    • Francisca TM Pereira, MD · Contacttatianap@baydenet.com.br
    • Eduardo A Rocha, MD · Contacteduardoa@cardiol.br
    • Francisca TM Pereira, MD · Principal investigator
    • Eduardo A Rocha, MD · Sub investigator
    • Marcelo P Monteiro, MD · Sub investigator
  • Instituto de Cardiologia do Distrito Federal
    Brasilia, DF, Brazil
    Recruiting
    • José M Baggio Jr, MD · Contactjmbaggio@cardiol.br
    • José M Baggio Jr, MD · Principal investigator
    • Renato Bueno, MD · Sub investigator
  • Anis Rassi Hospital
    Goiania, GO, Brazil
    Not yet recruiting
    • Anis Rassi Jr, MD, PhD · Contactarassijr@terra.com.br
    • Anis Rassi Jr, MD, PhD · Principal investigator
  • Hospital das Clínicas de Goiania
    Goiania, GO, Brazil
    Recruiting
    • Salvador Rassi, MD, PhD · Contactsrassi@cardiol.br
    • Salvador Rassi, MD, PhD · Principal investigator
  • Santa Casa de Goiania
    Goiania, GO, Brazil
    Not yet recruiting
  • Hospital Felício Rocho
    Belo Horizonte, MG, Brazil
    Not yet recruiting
  • Hospital das Clínicas Samuel Libânio
    Pouso Alegre, MG, Brazil
    Not yet recruiting
  • Hospital Escola da Universidade Federal do Triângulo Mineiro
    Uberaba, MG, Brazil
    Not yet recruiting
  • Hospital Geral Universitário
    Cuiabá, Mount, Brazil
    Not yet recruiting
  • Hospital Universitário Procape
    Recife, PE, Brazil
    Not yet recruiting
    • Dário Sobral Filho, MD, PhD · Contactdsobral@uol.com.br
    • Abelardo G Escarião, MD · Contactescariao@hotmail.com
    • Dário C Sobral Filho, MD, PhD · Principal investigator
    • Adelardo G Escariao, MD · Sub investigator
    • Antonio M Nascimento, MD · Sub investigator
    • Wilson A Oliveira Jr, MD · Sub investigator
  • Hospital Santa Casa de Misericórdia de Curitiba
    Curitiba, PR, Brazil
    Not yet recruiting
    • Gerson Lemke, MD · Contact
    • José CM Jorge, MD, PhD · Contactmourajorge@terra.com.br
    • Gerson Lemke, MD · Principal investigator
    • José CM Jorge, MD, PhD · Sub investigator
  • Hospital das Clínicas da UNICAMP
    Campinas, SP, Brazil
    Not yet recruiting
    • Márcio JO Figueiredo, MD, PhD · Contactmjofig@gmail.com
    • Márcio JO Figueiredo, MD, PhD · Principal investigator
    • Otávio R Coelho, MD · Sub investigator
  • Santa Casa de Ribeirão Preto
    Ribeirão Preto, SP 14080-000, Brazil
    Not yet recruiting
    • Antonio Vitor Moraes Jr, MD, PhD · Contactavitor@terra.com.br · +55 16 97920407
    • Antonio Vitor Moraes Jr, MD, PhD · Principal investigator
  • HC - FMUSP / Ribeirão Preto
    Ribeirão Preto, SP, Brazil
    Recruiting
    • José A Marin-Neto, MD, FullProf · Contactmarin_neto@yahoo.com
    • Marcelo G Leal, MD, PhD · Contactmgleal@cardiol.br
    • José A Marin-Neto, MD, FullProf · Principal investigator
    • Marcelo G Leal, MD, PhD · Principal investigator
    • Elerson Arfelli, MD · Sub investigator
    • Andre Schmidt, MD, PhD · Sub investigator
    • Adilson Escorzonic, MD · Sub investigator
    • Jairo R Silva Jr, MD · Sub investigator
    • Henrique T Moreira, MD · Sub investigator
    • Maria LC Pavao, MD · Sub investigator
  • Instituto de Moléstias Cardiovasculares
    São José do Rio Preto, SP, Brazil
    Recruiting
  • Heart Institute (InCor) - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, SP 05403000, Brazil
    Recruiting
    • Martino Martinelli, MD, PhD · Contactmartino@incor.usp.br · 55 11 26615515
    • Sergio F Siqueira, Eng, MsC · Contactsiqueira@incor.usp.br · 55 11 26615514
    • Sérgio F Siqueira, Eng, MsC · Sub investigator
    • Giselle L Peixoto, MD · Sub investigator
    • Roberto Costa, MD, PhD · Sub investigator
    • Maurício I Scanavacca, MD, PhD · Sub investigator
    • Barbara M Ianni, MD, PhD · Sub investigator
    • Edmar Bocchi, MD, PhD · Sub investigator
    • Fernando Bacal, MD, PhD · Sub investigator
    • Francisco CC Darriex, MD, PhD · Sub investigator
    • Silvana AD Nishioka, MD, PhD · Sub investigator
    • Anisio AA Pedrosa, MD, PhD · Sub investigator
    • Ricardo A Teixeira, MD, PhD · Sub investigator
    • Jose Antonio Marin-Neto, Prof · Principal investigator
  • Beneficiência Portuguesa
    São Paulo, SP, Brazil
    Not yet recruiting
    • Silas S Galvão Filho, MD · Contactsdsantos@uol.com.br
    • José TM Vasconcelos, MD, PhD · Contacttarr@terra.com.br
    • Silas S Galvão Filho · Principal investigator
    • José TM Vasconcelos, MD, PhD · Sub investigator
  • Escola Paulista de Medicina
    São Paulo, SP, Brazil
    Recruiting
    • Angelo Paola, MD, FullProf · Contactdepaola@uol.com.br
    • Guilherme Fenelon, MD, PhD · Contactguilhermefenelon@uol.com.br
    • Angelo Paola, MD, FullProf · Principal investigator
    • Guilherme Fenelon, MD, PhD · Sub investigator
  • Instituto Dante Pazzanese de Cardiologia
    São Paulo, SP, Brazil
    Recruiting
08

References and documents

Publications

  • Martinelli M, Rassi A Jr, Marin-Neto JA, de Paola AA, Berwanger O, Scanavacca MI, Kalil R, de Siqueira SF. CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial. Am Heart J. 2013 Dec;166(6):976-982.e4. doi: 10.1016/j.ahj.2013.08.027. Epub 2013 Oct 11. PubMed 24268211 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2014 (actual). Primary completion is estimated for Jul 2022, 93 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2012
First posted
Nov 7, 2012
StartActual
Oct 6, 2014
Primary completionEst.
Jul 31, 2022
CompletionEst.
Jul 31, 2022
Last update
Aug 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01722942
Lead sponsor
InCor Heart Institute
Collaborators
Ministry of Health, Brazil, Abbott Medical Devices
Responsible party
Martino Martinelli Filho (PhD, MD, InCor Heart Institute) — Principal investigator
First posted
Nov 7, 2012
Start date
Oct 6, 2014
Primary completion
Jul 31, 2022 (estimated)
Completion
Jul 31, 2022 (estimated)
Last update
Aug 30, 2021

Study contacts

Martino Martinelli, MD, PhD
Contact
martino@incor.usp.br
55 11 26615515
Sergio F Siqueira, Eng, MsC
Contact
siqueira@incor.usp.br
55 11 26615514
Martino Martinelli, Prof.
principal investigator · InCor Heart Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion